Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization
Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-01, Vol.15 (1), p.e0227711-e0227711 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0227711 |
|---|---|
| container_issue | 1 |
| container_start_page | e0227711 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Lanza, Ezio Muglia, Riccardo Bolengo, Isabella Poretti, Dario D'Antuono, Felice Ceriani, Roberto Torzilli, Guido Pedicini, Vittorio |
| description | Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to the absence of chemotherapy. However, few studies have reported data on TAE monotherapy for unresectable HCC. We report our results in a cohort of 230 patients with unresectable HCC treated with TAE (TAE with 40-100micron microparticles, TAE with microparticles plus n-butyl-2-cyanoacrylate, TAE with Lipiodol) over the course of seven years. Thirty-seven patients (14%) were down-staged during observation and also received a percutaneous ablation. We observed 1-, 2-, 3-, 4- and 5-year rates of 84,8%, 58,7%, 38,3%, 28,3%, and 18,7%. Patients who also received percutaneous treatment performed best. Our results broaden the body of evidence for the use of TAE in advanced HCC. |
| doi_str_mv | 10.1371/journal.pone.0227711 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2337981698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A611307190</galeid><doaj_id>oai_doaj_org_article_4035352535a742cda7dabff4c3cf54ef</doaj_id><sourcerecordid>A611307190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-a36241c8c2d12b51e636491f487802478f60168aecc16524159520ac7c19ece83</originalsourceid><addsrcrecordid>eNqNk01v1DAQhiMEoqXwDxBEQkJw2MUfiZNckKqKj5UqVaLA1Zo4k11XTrzYzkL763G6abVBPaAcEs08847njSdJXlKypLygH67s4Howy63tcUkYKwpKHyXHtOJsIRjhjw--j5Jn3l8RkvNSiKfJEY-ZnOX5cXJzObid3oFJIYpde-1T26aMk3QLQWMffPpbh0069A49qgC1wXSDMWkVGjMYcKkCp3RvO0iDQwjY7EtqA30TQ9B7cAGdjk2wq63RN1Ha9s-TJy0Yjy-m90ny4_On72dfF-cXX1Znp-cLJSoWFsAFy6gqFWsoq3OKgousom1WFiVhWVG2glBRAipFRR7RvMoZAVUoWqHCkp8kr_e6W2O9nGzzknFeVCUV1Uis9kRj4Upune7AXUsLWt4GrFvLOIFWBmVGeD5ax3MoMqYaKBqo2zZTXLV5hm3U-jh1G-oOGxUtdGBmovNMrzdybXdSVPHgZRYF3k0Czv4a0AfZaT96DT3a4fbcFSGioDyib_5BH55uotYQB9B9a2NfNYrKU0EpJwWtSKSWD1DxabDTKt6xVsf4rOD9rCAyAf-ENQzey9Xlt_9nL37O2bcH7AbBhI23ZhivjJ-D2R5UznrvsL03mRI5rsidG3JcETmtSCx7dfiD7ovudoL_Be7PDN0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2337981698</pqid></control><display><type>article</type><title>Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lanza, Ezio ; Muglia, Riccardo ; Bolengo, Isabella ; Poretti, Dario ; D'Antuono, Felice ; Ceriani, Roberto ; Torzilli, Guido ; Pedicini, Vittorio</creator><contributor>Alpini, Gianfranco D.</contributor><creatorcontrib>Lanza, Ezio ; Muglia, Riccardo ; Bolengo, Isabella ; Poretti, Dario ; D'Antuono, Felice ; Ceriani, Roberto ; Torzilli, Guido ; Pedicini, Vittorio ; Alpini, Gianfranco D.</creatorcontrib><description>Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to the absence of chemotherapy. However, few studies have reported data on TAE monotherapy for unresectable HCC. We report our results in a cohort of 230 patients with unresectable HCC treated with TAE (TAE with 40-100micron microparticles, TAE with microparticles plus n-butyl-2-cyanoacrylate, TAE with Lipiodol) over the course of seven years. Thirty-seven patients (14%) were down-staged during observation and also received a percutaneous ablation. We observed 1-, 2-, 3-, 4- and 5-year rates of 84,8%, 58,7%, 38,3%, 28,3%, and 18,7%. Patients who also received percutaneous treatment performed best. Our results broaden the body of evidence for the use of TAE in advanced HCC.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0227711</identifier><identifier>PMID: 31935255</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Ablation ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Biology and Life Sciences ; Cancer ; Cancer treatment ; Carcinoma ; Carcinoma, Hepatocellular - therapy ; Cardiovascular system ; Care and treatment ; Chemoembolization, Therapeutic - methods ; Chemotherapy ; Digital archives ; Embolization ; Ethiodized Oil - administration & dosage ; Ethiodized Oil - therapeutic use ; Female ; Hepatocellular carcinoma ; Hospitals ; Humans ; Liver cancer ; Liver Neoplasms - therapy ; Male ; Medical imaging ; Medicine and Health Sciences ; Microparticles ; Middle Aged ; Nitriles ; Patient outcomes ; Patients ; Percutaneous treatment ; Physical Sciences ; Radiology ; Research and Analysis Methods ; Social Sciences ; Supervision ; Survival Analysis ; Veins & arteries</subject><ispartof>PloS one, 2020-01, Vol.15 (1), p.e0227711-e0227711</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Lanza et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Lanza et al 2020 Lanza et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-a36241c8c2d12b51e636491f487802478f60168aecc16524159520ac7c19ece83</citedby><cites>FETCH-LOGICAL-c692t-a36241c8c2d12b51e636491f487802478f60168aecc16524159520ac7c19ece83</cites><orcidid>0000-0003-1889-8798</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959584/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959584/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31935255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Alpini, Gianfranco D.</contributor><creatorcontrib>Lanza, Ezio</creatorcontrib><creatorcontrib>Muglia, Riccardo</creatorcontrib><creatorcontrib>Bolengo, Isabella</creatorcontrib><creatorcontrib>Poretti, Dario</creatorcontrib><creatorcontrib>D'Antuono, Felice</creatorcontrib><creatorcontrib>Ceriani, Roberto</creatorcontrib><creatorcontrib>Torzilli, Guido</creatorcontrib><creatorcontrib>Pedicini, Vittorio</creatorcontrib><title>Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to the absence of chemotherapy. However, few studies have reported data on TAE monotherapy for unresectable HCC. We report our results in a cohort of 230 patients with unresectable HCC treated with TAE (TAE with 40-100micron microparticles, TAE with microparticles plus n-butyl-2-cyanoacrylate, TAE with Lipiodol) over the course of seven years. Thirty-seven patients (14%) were down-staged during observation and also received a percutaneous ablation. We observed 1-, 2-, 3-, 4- and 5-year rates of 84,8%, 58,7%, 38,3%, 28,3%, and 18,7%. Patients who also received percutaneous treatment performed best. Our results broaden the body of evidence for the use of TAE in advanced HCC.</description><subject>Ablation</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>Cancer</subject><subject>Cancer treatment</subject><subject>Carcinoma</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cardiovascular system</subject><subject>Care and treatment</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Chemotherapy</subject><subject>Digital archives</subject><subject>Embolization</subject><subject>Ethiodized Oil - administration & dosage</subject><subject>Ethiodized Oil - therapeutic use</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine and Health Sciences</subject><subject>Microparticles</subject><subject>Middle Aged</subject><subject>Nitriles</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Percutaneous treatment</subject><subject>Physical Sciences</subject><subject>Radiology</subject><subject>Research and Analysis Methods</subject><subject>Social Sciences</subject><subject>Supervision</subject><subject>Survival Analysis</subject><subject>Veins & arteries</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk01v1DAQhiMEoqXwDxBEQkJw2MUfiZNckKqKj5UqVaLA1Zo4k11XTrzYzkL763G6abVBPaAcEs08847njSdJXlKypLygH67s4Howy63tcUkYKwpKHyXHtOJsIRjhjw--j5Jn3l8RkvNSiKfJEY-ZnOX5cXJzObid3oFJIYpde-1T26aMk3QLQWMffPpbh0069A49qgC1wXSDMWkVGjMYcKkCp3RvO0iDQwjY7EtqA30TQ9B7cAGdjk2wq63RN1Ha9s-TJy0Yjy-m90ny4_On72dfF-cXX1Znp-cLJSoWFsAFy6gqFWsoq3OKgousom1WFiVhWVG2glBRAipFRR7RvMoZAVUoWqHCkp8kr_e6W2O9nGzzknFeVCUV1Uis9kRj4Upune7AXUsLWt4GrFvLOIFWBmVGeD5ax3MoMqYaKBqo2zZTXLV5hm3U-jh1G-oOGxUtdGBmovNMrzdybXdSVPHgZRYF3k0Czv4a0AfZaT96DT3a4fbcFSGioDyib_5BH55uotYQB9B9a2NfNYrKU0EpJwWtSKSWD1DxabDTKt6xVsf4rOD9rCAyAf-ENQzey9Xlt_9nL37O2bcH7AbBhI23ZhivjJ-D2R5UznrvsL03mRI5rsidG3JcETmtSCx7dfiD7ovudoL_Be7PDN0</recordid><startdate>20200114</startdate><enddate>20200114</enddate><creator>Lanza, Ezio</creator><creator>Muglia, Riccardo</creator><creator>Bolengo, Isabella</creator><creator>Poretti, Dario</creator><creator>D'Antuono, Felice</creator><creator>Ceriani, Roberto</creator><creator>Torzilli, Guido</creator><creator>Pedicini, Vittorio</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1889-8798</orcidid></search><sort><creationdate>20200114</creationdate><title>Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization</title><author>Lanza, Ezio ; Muglia, Riccardo ; Bolengo, Isabella ; Poretti, Dario ; D'Antuono, Felice ; Ceriani, Roberto ; Torzilli, Guido ; Pedicini, Vittorio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-a36241c8c2d12b51e636491f487802478f60168aecc16524159520ac7c19ece83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ablation</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>Cancer</topic><topic>Cancer treatment</topic><topic>Carcinoma</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cardiovascular system</topic><topic>Care and treatment</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Chemotherapy</topic><topic>Digital archives</topic><topic>Embolization</topic><topic>Ethiodized Oil - administration & dosage</topic><topic>Ethiodized Oil - therapeutic use</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine and Health Sciences</topic><topic>Microparticles</topic><topic>Middle Aged</topic><topic>Nitriles</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Percutaneous treatment</topic><topic>Physical Sciences</topic><topic>Radiology</topic><topic>Research and Analysis Methods</topic><topic>Social Sciences</topic><topic>Supervision</topic><topic>Survival Analysis</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanza, Ezio</creatorcontrib><creatorcontrib>Muglia, Riccardo</creatorcontrib><creatorcontrib>Bolengo, Isabella</creatorcontrib><creatorcontrib>Poretti, Dario</creatorcontrib><creatorcontrib>D'Antuono, Felice</creatorcontrib><creatorcontrib>Ceriani, Roberto</creatorcontrib><creatorcontrib>Torzilli, Guido</creatorcontrib><creatorcontrib>Pedicini, Vittorio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanza, Ezio</au><au>Muglia, Riccardo</au><au>Bolengo, Isabella</au><au>Poretti, Dario</au><au>D'Antuono, Felice</au><au>Ceriani, Roberto</au><au>Torzilli, Guido</au><au>Pedicini, Vittorio</au><au>Alpini, Gianfranco D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-01-14</date><risdate>2020</risdate><volume>15</volume><issue>1</issue><spage>e0227711</spage><epage>e0227711</epage><pages>e0227711-e0227711</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Locoregional therapies for hepatocellular carcinoma (HCC) include endovascular treatments such as chemoembolization (TACE) and bland embolization (TAE). TACE is the most adopted technique, despite a lack of definitive evidence of superiority over TAE, which is less costly and better tolerated due to the absence of chemotherapy. However, few studies have reported data on TAE monotherapy for unresectable HCC. We report our results in a cohort of 230 patients with unresectable HCC treated with TAE (TAE with 40-100micron microparticles, TAE with microparticles plus n-butyl-2-cyanoacrylate, TAE with Lipiodol) over the course of seven years. Thirty-seven patients (14%) were down-staged during observation and also received a percutaneous ablation. We observed 1-, 2-, 3-, 4- and 5-year rates of 84,8%, 58,7%, 38,3%, 28,3%, and 18,7%. Patients who also received percutaneous treatment performed best. Our results broaden the body of evidence for the use of TAE in advanced HCC.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>31935255</pmid><doi>10.1371/journal.pone.0227711</doi><tpages>e0227711</tpages><orcidid>https://orcid.org/0000-0003-1889-8798</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-01, Vol.15 (1), p.e0227711-e0227711 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2337981698 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Ablation Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biology and Life Sciences Cancer Cancer treatment Carcinoma Carcinoma, Hepatocellular - therapy Cardiovascular system Care and treatment Chemoembolization, Therapeutic - methods Chemotherapy Digital archives Embolization Ethiodized Oil - administration & dosage Ethiodized Oil - therapeutic use Female Hepatocellular carcinoma Hospitals Humans Liver cancer Liver Neoplasms - therapy Male Medical imaging Medicine and Health Sciences Microparticles Middle Aged Nitriles Patient outcomes Patients Percutaneous treatment Physical Sciences Radiology Research and Analysis Methods Social Sciences Supervision Survival Analysis Veins & arteries |
| title | Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T09%3A37%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20analysis%20of%20230%20patients%20with%20unresectable%20hepatocellular%20carcinoma%20treated%20with%20bland%20transarterial%20embolization&rft.jtitle=PloS%20one&rft.au=Lanza,%20Ezio&rft.date=2020-01-14&rft.volume=15&rft.issue=1&rft.spage=e0227711&rft.epage=e0227711&rft.pages=e0227711-e0227711&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0227711&rft_dat=%3Cgale_plos_%3EA611307190%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2337981698&rft_id=info:pmid/31935255&rft_galeid=A611307190&rft_doaj_id=oai_doaj_org_article_4035352535a742cda7dabff4c3cf54ef&rfr_iscdi=true |